Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
BioSig Technologies 4.67M share Spot Secondary priced at $0.75 » 09:39
06/24/22
06/24
09:39
06/24/22
09:39
BSGM

BioSig Technologies

$1.01 /

+0.11 (+12.22%)

Laidlaw is acting as sole…

Laidlaw is acting as sole book running manager for the offering.

ShowHide Related Items >><<
BSGM BioSig Technologies
$1.01 /

+0.11 (+12.22%)

  • 24
    Jun
  • 02
    Jul
BSGM BioSig Technologies
$1.01 /

+0.11 (+12.22%)

Syndicate
BioSig Technologies announces common stock offering, no amount given » 16:27
06/23/22
06/23
16:27
06/23/22
16:27
BSGM

BioSig Technologies

$1.01 /

+0.11 (+12.22%)

BioSig Technologies…

BioSig Technologies announced that it intends to offer shares of its common stock in a "best efforts" underwritten public offering. Laidlaw & Company is acting as sole book-running manager for the offering. BioSig intends to use the net proceeds from the offering for the continuation of commercialization activities related to the PURE EP System, including additional support for organizational development, to fund working capital, and for general corporate purposes and other capital expenditures.

ShowHide Related Items >><<
BSGM BioSig Technologies
$1.01 /

+0.11 (+12.22%)

  • 02
    Jul
BSGM BioSig Technologies
$1.01 /

+0.11 (+12.22%)

Hot Stocks
BioSig enters new evaluation agreement for PURE EP with Cleveland clinic » 08:09
06/22/22
06/22
08:09
06/22/22
08:09
BSGM

BioSig Technologies

/

+

BioSig Technologies…

BioSig Technologies announced it has entered an evaluation agreement for its PURE EP System with the Cleveland Clinic. The evaluation agreement marks the first since BioSig inducted a new commercialization team. Consistent with The Company's stated national rollout strategy, Cleveland Clinic will participate in a 60-day evaluation of BioSig's PURE EP System. The Company recently announced that is has restructured its clinical support and installation teams to streamline and accelerate the pathway from product evaluation to adoption. "We are excited to include Cleveland Clinic as an evaluation center for the Pure EP System. We look forward to working alongside their physicians to demonstrate the superior signal quality that can be achieved on even the most difficult arrhythmias," commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies.

ShowHide Related Items >><<
BSGM BioSig Technologies
/

+

  • 02
    Jul
BSGM BioSig Technologies
/

+

Over a month ago
Hot Stocks
BioSig Technologies rolls out national commercial launch campaign » 09:13
05/26/22
05/26
09:13
05/26/22
09:13
BSGM

BioSig Technologies

$1.16 /

+0.06 (+5.45%)

BioSig Technologies…

BioSig Technologies announced the rollout of the Company's national commercial launch campaign. Under the leadership of its Chief Commercial Officer Gray Fleming, BioSig has implemented several important initiatives to accelerate the transition from its limited market release to a national launch of its PURE EP System. The Company currently has over 30 qualified leads ahead of its official commercial kick-off, expected to commence on July 1, 2022. The PURE EP is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP System. Commercial strategy highlights include: Business agreement with Summit Blue Capital to implement a leasing and finance program for the PURE EP System. The agreement aims to expedite the pathway to purchase and increase the of scope PURE EP adopters across the U.S. Streamlined product evaluations from 180-360 days to 60 days with a succinct clinical and economic value proposition that showcases the advantages of the technology and accelerates adoption. Strengthened management, commercial, clinical, and marketing teams under the leadership of Gray Fleming, Chief Commercial Officer, who spent 18 years with St. Jude Medical/Abbott. Restructured clinical support and installation teams in preparation for increased commercial activity. The Company's new commercial structure includes national account directors covering five regions in the United States to support product evaluations and the rapid transformation of qualified leads into sales. Implemented an effective CRM system and pipeline management system to support sales opportunities and streamline data and customer engagements. Company to implement new brand strategy and marketing programs to reflect business growth and evolution. These efforts include an updated website and new visual content and branding.

ShowHide Related Items >><<
BSGM BioSig Technologies
$1.16 /

+0.06 (+5.45%)

  • 02
    Jul
BSGM BioSig Technologies
$1.16 /

+0.06 (+5.45%)

Hot Stocks
BioSig: PURE EP system has completed over 2,200 patient cases » 08:36
05/11/22
05/11
08:36
05/11/22
08:36
BSGM

BioSig Technologies

/

+

To date, company's…

To date, company's FDA 510(k) cleared PURE EP system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States, BioSig said in a statement. "We have made great strides on multiple fronts and felt it was an important time to communicate to our shareholders the strength of our business and the initiatives we are executing that have served as the foundation for our growth trajectory," said Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. "We strongly believe in the value of our technology and are now supported with both peer-reviewed clinical data and third-party economic data, proving the value of what we have built. We are eager to continue working on our new commercialization strategy, seeing the impact of our new NOVA-5 software has, and all our initiatives we are undertaking to drive shareholder value and expand PURE EP."

ShowHide Related Items >><<
BSGM BioSig Technologies
/

+

  • 02
    Jul
BSGM BioSig Technologies
/

+

Over a quarter ago
On The Fly
Meet BioSig Technologies: Fly exclusive interview with CEO Ken Londoner » 13:03
03/31/22
03/31
13:03
03/31/22
13:03
ABT

Abbott

$120.13 /

-0.25 (-0.21%)

, BSGM

BioSig Technologies

$1.19 /

-0.05 (-4.03%)

In an exclusive interview…

ShowHide Related Items >><<
BSGM BioSig Technologies
$1.19 /

-0.05 (-4.03%)

ABT Abbott
$120.13 /

-0.25 (-0.21%)

ABT Abbott
$120.13 /

-0.25 (-0.21%)

03/01/22 BofA
Abbott reinstated with a Buy at BofA
02/02/22 Piper Sandler
Boston Scientific thesis unchanged despite margin outlook, says Piper Sandler
01/27/22 Raymond James
Abbott price target lowered to $143 from $150 at Raymond James
01/26/22 BTIG
Abbott price target lowered to $138 from $143 at BTIG
BSGM BioSig Technologies
$1.19 /

-0.05 (-4.03%)

ABT Abbott
$120.13 /

-0.25 (-0.21%)

  • 02
    Jul
ABT Abbott
$120.13 /

-0.25 (-0.21%)

ABT Abbott
$120.13 /

-0.25 (-0.21%)

ABT Abbott
$120.13 /

-0.25 (-0.21%)

Hot Stocks
BioSig CEO sees 'massive amount of pent-up demand' in industry  13:00
03/31/22
03/31
13:00
03/31/22
13:00
BSGM

BioSig Technologies

$1.19 /

-0.05 (-4.03%)

 
ShowHide Related Items >><<
BSGM BioSig Technologies
$1.19 /

-0.05 (-4.03%)

  • 02
    Jul
Hot Stocks
BioSig shifting from R&D to commercial launch, CEO tells The Fly  13:00
03/31/22
03/31
13:00
03/31/22
13:00
BSGM

BioSig Technologies

$1.19 /

-0.05 (-4.03%)

 
ShowHide Related Items >><<
BSGM BioSig Technologies
$1.19 /

-0.05 (-4.03%)

  • 02
    Jul
Hot Stocks
BioSig CEO says recent financing gives enough runway to ramp commercial activity  13:00
03/31/22
03/31
13:00
03/31/22
13:00
BSGM

BioSig Technologies

$1.19 /

-0.05 (-4.03%)

 
ShowHide Related Items >><<
BSGM BioSig Technologies
$1.19 /

-0.05 (-4.03%)

  • 02
    Jul
Hot Stocks
BioSig seeing double-digit increases in elective procedure growth, CEO says  13:00
03/31/22
03/31
13:00
03/31/22
13:00
BSGM

BioSig Technologies

$1.19 /

-0.05 (-4.03%)

 
ShowHide Related Items >><<
BSGM BioSig Technologies
$1.19 /

-0.05 (-4.03%)

  • 02
    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.